The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.M. has acted as an advisor for Bayer AG, Lilly Deutschland, Novartis and Novo Nordisk; has received honoraria from Ärztekammer Nordrhein, AstraZeneca, Boehringer Ingelheim, Deutsche Diabetes Gesellschaft, Eli Lilly, MSD, Novartis and Novo Nordisk and has had travel costs reimbursed by AstraZeneca and Novo Nordisk. T.L.B. and A.M.C. are employees of Novo Nordisk A/S and own stock in the company. S.P. is an employee of Novo Nordisk Pharma GmbH and owns stock in the company. J.S. has received lecture fees and congress invitations from Almirall, Allergika, Amgen, Astellas, AstraZeneca, BMS, Bayer, Baxter, Berlin-Chemie, Boehringer Ingelheim, Eli Lilly, FORTBILDUNGSKOLLEG Praxis-Depesche, GSK, KWHC, Medical Tribune, MSD, Infectopharm, Dr Kade/Besins Pharma, Novo Nordisk, Novartis, OmniaMed, Praxis-Depesche, Recordati Pharma, Roche Diagnostics, Sanofi-Aventis and Taurus Pharma; funding for clinical studies from Amgen, AstraZeneca, BMS, Covance, Eli Lilly, ICON, Janssen-Cilag, HANMI, MSD, Novartis, Novo Nordisk, Parexel, Pharmalog, Pfizer, Roche, Sanofi-Aventis and SiteWorks; and has served on an Advisory Board for Amgen, Bayer, Boehringer Ingelheim, Bristol-Myer-Squibb, Dexcom, Janssen-Cilag, MSD, LifeScan, Eli Lilly, Novo Nordisk, Roche Diagnostics, Pfizer and Sanofi-Aventis. S.J. has received honoraria, research support and consulting fees from Amarin, Amgen, AstraZeneca, Bayer, BMS, Berlin Chemie, Boehringer Ingelheim, Lilly, Merck, MSD, Novo Nordisk, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier and Vifor.
PubMed
